Review article

https://doi.org/10.5599/admet.4.2.337

Tyrosine kinase inhibitors for EGFR- and ALK-mutated non-small cell lung cancer

Jonathan R. Thompson ; Mazie Froedtert Willms &Sue Froedtert Cancer Fellow at Froedtert Hospital, Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
Smitha P. Menon ; Division of Hematology and Oncology, Medical College of Wisconsin, Milwaukee, WI
Grace K. Dy ; 3Department of Medicine, Roswell Park Cancer Institute, Buffalo, NY

Abstract

Discovery of the epidermal growth receptor (EGFR) activating mutations and anaplastic lymphoma kinase (ALK) rearrangements has expanded the therapeutic landscape in non-small cell lung cancer (NSCLC). Survival outcomes for patients with these mutations have improved dramatically with EGFR and ALK tyrosine kinase inhibitors (TKIs). Multiple generations of EGFR and ALK TKIs have been rapidly developed, and patients and clinicians now have several options for first- and second-line treatments. While these small molecule TKIs have some similarities in therapeutic and pharmacologic profiles, the differences can be clinically substantial, allowing tailored treatment for each unique patient. This review details the clinical efficacy, pharmacology, safety profiles, CNS penetration, and mechanisms of resistance of the four EGFR TKIs and three ALK TKIs that are currently approved by the United States Food and Drug Administration (US FDA).

Keywords

Epidermal growth factor receptor; Anaplastic lymphoma kinase; targeted therapy

Hrčak ID:

167042

URI

https://hrcak.srce.hr/167042

Publication date:

30.9.2016.

Visits: 2.204 *